Journal of Attention Disorders

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1087054706295663v1
11/2/157    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Faraone, S. V.
Right arrow Articles by Zimmerman, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Faraone, S. V.
Right arrow Articles by Zimmerman, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on September 1, 2007
Journal of Attention Disorders, Vol. 11, No. 2, 157-166 (2007)
DOI: 10.1177/1087054706295663

An Analysis of Patient Adherence to Treatment During a 1-Year, Open-label Study of OROS® Methylphenidate in Children With ADHD

Stephen V. Faraone, PhD

SUNY Upstate Medical University, faraones{at}upstate.edu

Joseph Biederman, MD

Massachusetts General Hospital

Brenda Zimmerman

McNeil Consumer & Specialty Phamaceuticals

Objective: Treatment adherence is an important aspect of ADHD symptom management, but there are many factors that may influence adherence. Method: This analysis assessed adherence to OROS methylphenidate during a 1-year, open-label study in children. Adherence was defined as the number of days medication was taken divided by the number of days in the study and determined to be high if ≥75%. Possible clinical and demographic factors associated with adherence, including use of planned medication breaks, were assessed. Results: Mean adherence was 86.4%. It was 91.6% for the subgroup of patients who reported not taking planned medication breaks (n = 252) and 77.7% for the subgroup taking planned medication breaks (n = 155). Overall, 75% of patients showed high adherence. Older age, low starting dose, minority ethnic status, and fewer ADHD symptoms were associated with low adherence. Conclusion: Various factors were found to be associated with low adherence, and the results of this analysis provide guidance to physicians seeking to identify those patients with ADHD most likely not be adherent to stimulant therapy (J. of Att. Dis. 2007; 11(2) 157-166)

Key Words: methylphenidate • attention deficit/hyperactivity disorder • children • treatment


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?